Russell Investments Group
RXRX icon

Russell Investments Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Russell Investments Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$541K Buy
147,463
+82,473
+127% +$275K ﹤0.01% 2736
2026
Q1 		$200K Sell
64,990
-8,283
-11% -$32K ﹤0.01% 2852
2025
Q4 		$300K Buy
73,273
+25,240
+53% +$125K ﹤0.01% 2679
2025
Q3 		$234K Buy
48,033
+37,251
+345% +$196K ﹤0.01% 2757
2025
Q2 		$54.6K Sell
10,782
-28,116
-72% -$138K ﹤0.01% 2965
2025
Q1 		$206K Sell
38,898
-157,754
-80% -$1.15M ﹤0.01% 2586
2024
Q4 		$1.33M Sell
196,652
-41,446
-17% -$279K ﹤0.01% 1865
2024
Q3 		$1.57M Buy
238,098
+89,335
+60% +$640K ﹤0.01% 1810
2024
Q2 		$1.12M Sell
148,763
-9,542
-6% -$83.2K ﹤0.01% 1924
2024
Q1 		$1.58M Buy
158,305
+49,292
+45% +$549K ﹤0.01% 1770
2023
Q4 		$1.07M Sell
109,013
-21,888
-17% -$156K ﹤0.01% 1933
2023
Q3 		$1M Buy
130,901
+55,600
+74% +$555K ﹤0.01% 1927
2023
Q2 		$562K Sell
75,301
-56,655
-43% -$396K ﹤0.01% 2184
2023
Q1 		$880K Hold
131,956
– – ﹤0.01% 2039
2022
Q4 		$1.02M Sell
131,956
-3,117
-2% -$30.6K ﹤0.01% 1965
2022
Q3 		$1.44M Buy
135,073
+6,536
+5% +$66.2K ﹤0.01% 1748
2022
Q2 		$1.04M Buy
+128,537
New +$860K ﹤0.01% 1943
2022
Q1 		– Sell
-34,166
Closed -$584K – 2901
2021
Q4 		$584K Buy
34,166
+2,633
+8% +$49.5K ﹤0.01% 2387
2021
Q3 		$725K Hold
31,533
– – ﹤0.01% 2332
2021
Q2 		$1.15M Buy
+31,533
New +$933K ﹤0.01% 2244

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Russell Investments Group's RXRX Position: Q2 2026 in Review

Russell Investments Group increased its Recursion Pharmaceuticals (RXRX) stake by 127% in Q2 2026, buying an estimated $275K and bringing the position to 147,463 shares worth $541K. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

Russell Investments Group first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.58M in Q1 2024. 186 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Russell Investments Group held 147,463 shares of Recursion Pharmaceuticals worth $541K as of Q2 2026.
  • Russell Investments Group bought 82,473 Recursion Pharmaceuticals shares in Q2 2026, an estimated $275K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2736 holding.
  • Russell Investments Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Russell Investments Group's Recursion Pharmaceuticals position peaked at $1.58M in Q1 2024.
  • 186 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.